Nothing Special   »   [go: up one dir, main page]

DE60237929D1 - Cell proliferation inhibitors containing anti-glypican 3 antibodies - Google Patents

Cell proliferation inhibitors containing anti-glypican 3 antibodies

Info

Publication number
DE60237929D1
DE60237929D1 DE60237929T DE60237929T DE60237929D1 DE 60237929 D1 DE60237929 D1 DE 60237929D1 DE 60237929 T DE60237929 T DE 60237929T DE 60237929 T DE60237929 T DE 60237929T DE 60237929 D1 DE60237929 D1 DE 60237929D1
Authority
DE
Germany
Prior art keywords
glypican
antibodies
cell proliferation
proliferation inhibitors
containing anti
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60237929T
Other languages
German (de)
Inventor
Hiroyuki Aburatani
Tetsuo Nakamura
Masayuki Tsuchiya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE60237929D1 publication Critical patent/DE60237929D1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Cell-proliferation inhibitors contain anti-glypican 3 antibody as active ingredient, are new. An independent claim is also included for an antibody with cytotoxicity. ACTIVITY : Cytostatic. No Biological data is given. MECHANISM OF ACTION : None given in source material.
DE60237929T 2001-06-22 2002-06-21 Cell proliferation inhibitors containing anti-glypican 3 antibodies Expired - Lifetime DE60237929D1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001189443 2001-06-22

Publications (1)

Publication Number Publication Date
DE60237929D1 true DE60237929D1 (en) 2010-11-18

Family

ID=19028362

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60228721T Expired - Lifetime DE60228721D1 (en) 2001-06-22 2002-06-21 Zellproliferationsinhibitoren mit anti-glypican-3-antikörper
DE60237929T Expired - Lifetime DE60237929D1 (en) 2001-06-22 2002-06-21 Cell proliferation inhibitors containing anti-glypican 3 antibodies

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60228721T Expired - Lifetime DE60228721D1 (en) 2001-06-22 2002-06-21 Zellproliferationsinhibitoren mit anti-glypican-3-antikörper

Country Status (15)

Country Link
US (3) US20040236080A1 (en)
EP (3) EP2208784B1 (en)
JP (7) JP4281869B2 (en)
KR (3) KR100953520B1 (en)
CN (2) CN101240022B (en)
AT (2) ATE483801T1 (en)
AU (2) AU2002315857B2 (en)
CA (1) CA2451493C (en)
CY (1) CY1113854T1 (en)
DE (2) DE60228721D1 (en)
DK (2) DK2208784T3 (en)
ES (3) ES2312586T3 (en)
HK (2) HK1079547A1 (en)
PT (2) PT1411118E (en)
WO (1) WO2003000883A1 (en)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7361336B1 (en) * 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
CN101240022B (en) 2001-06-22 2012-07-18 中外制药株式会社 Cell proliferation inhibitors containing anti-glypican 3 antibody
MXPA04011132A (en) 2002-05-23 2005-08-15 Sunnybrook & Womens College Diagnosis of hepatocellular carcinoma.
AU2002338020A1 (en) * 2002-09-04 2004-03-29 Chugai Seiyaku Kabushiki Kaisha Antibody against blood-solubilized n-terminal peptide in gpc3
JPWO2005023301A1 (en) * 2003-09-04 2006-11-02 中外製薬株式会社 Bile duct cancer therapeutic agent and detection agent
NZ579543A (en) * 2004-07-09 2011-07-29 Chugai Pharmaceutical Co Ltd Anti-glypican 3 antibody
KR20130103580A (en) * 2004-08-24 2013-09-23 추가이 세이야쿠 가부시키가이샤 Adjuvant therapy with the use of anti-glypican 3 antibody
RU2451030C2 (en) * 2004-10-26 2012-05-20 Чугаи Сейяку Кабусики Кайся Anti-glypican 3-antibody having modified sugar chain
DK3050963T3 (en) 2005-03-31 2019-12-09 Chugai Pharmaceutical Co Ltd Process for producing polypeptide by arrangement control
KR20080035595A (en) 2005-08-03 2008-04-23 마츠시타 덴끼 산교 가부시키가이샤 Base station apparatus, communication terminal apparatus, and multicarrier communication method
US20070087005A1 (en) * 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
US7723043B2 (en) * 2006-01-04 2010-05-25 Picobella, Lp Methods for screening for prostate cancer
EP3345616A1 (en) 2006-03-31 2018-07-11 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
EP2006381B1 (en) 2006-03-31 2016-02-03 Chugai Seiyaku Kabushiki Kaisha Method for controlling blood pharmacokinetics of antibodies
PT2178921E (en) * 2007-07-17 2016-03-23 Squibb & Sons Llc Monoclonal antibodies against glypican-3
EP3689912A1 (en) 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
CL2008002886A1 (en) * 2007-09-26 2009-12-04 Chugai Pharmaceutical Co Ltd Constant region of a human antibody; anti-interleukin-6 (yl-6) receptor antibody and pharmaceutical composition comprising it.
EP2617736A1 (en) 2007-09-28 2013-07-24 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody having improved kinetics in plasma
DK2236604T3 (en) * 2007-12-05 2016-10-03 Chugai Pharmaceutical Co Ltd The anti-NR10 antibody and use thereof
CL2009000647A1 (en) * 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Pharmaceutical composition for treating or preventing liver cancer comprising a combination of a chemotherapeutic agent and an anti-glypican 3 antibody; agent for attenuating a side effect comprising said antibody; method of treating or preventing liver cancer of a subject.
KR102269708B1 (en) 2008-04-11 2021-06-25 추가이 세이야쿠 가부시키가이샤 Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
TWI440469B (en) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
TWI544077B (en) 2009-03-19 2016-08-01 Chugai Pharmaceutical Co Ltd Antibody constant region change body
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
WO2011037158A1 (en) 2009-09-24 2011-03-31 中外製薬株式会社 Modified antibody constant regions
EP2543730B1 (en) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US9334331B2 (en) 2010-11-17 2016-05-10 Chugai Seiyaku Kabushiki Kaisha Bispecific antibodies
CN107973851A (en) 2010-11-30 2018-05-01 中外制药株式会社 The antigen binding molecules of combination are repeated with polymolecular antigen
EP2647707B1 (en) 2010-11-30 2018-09-12 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
US20120190049A1 (en) * 2010-12-10 2012-07-26 University Of Washington Through Its Center For Commercialization Glypican-3 targeting of liver cancer cells using multifunctional nanoparticles
KR102147548B1 (en) 2011-02-25 2020-08-24 추가이 세이야쿠 가부시키가이샤 FcγRIIb-specific Fc antibody
EP2698431B1 (en) 2011-03-30 2020-09-09 Chugai Seiyaku Kabushiki Kaisha Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity
SG11201401101XA (en) 2011-09-30 2014-08-28 Chugai Pharmaceutical Co Ltd Antigen-binding molecule for promoting loss of antigens
TW201817744A (en) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
JP6322411B2 (en) 2011-09-30 2018-05-09 中外製薬株式会社 Antigen-binding molecules that promote the disappearance of antigens with multiple physiological activities
US10556949B2 (en) 2011-09-30 2020-02-11 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule inducing immune response to target antigen
EP3617313A1 (en) 2011-10-05 2020-03-04 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting clearance from plasma of antigen comprising saccharide chain receptor-binding domain
KR102475951B1 (en) 2012-02-24 2022-12-08 추가이 세이야쿠 가부시키가이샤 Antigen-binding molecule for promoting disappearance of antigen via FcγRIIB
RU2743463C2 (en) 2012-05-30 2021-02-18 Чугаи Сейяку Кабусики Кайся Antigen-binding molecule specific to target tissue
US9409994B2 (en) 2012-06-01 2016-08-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High-affinity monoclonal antibodies to glypican-3 and use thereof
TWI693073B (en) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 Therapeutic agent for GPC3 target is the effective therapeutic agent for GPC3 target administered to patients
EP3557260B1 (en) 2012-12-21 2022-05-18 Chugai Seiyaku Kabushiki Kaisha Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy
WO2015046467A1 (en) 2013-09-27 2015-04-02 中外製薬株式会社 Method for producing polypeptide heteromultimer
EA201691154A1 (en) 2013-12-04 2016-10-31 Чугаи Сейяку Кабусики Кайся ANTIGEN-BINDING MOLECULES, BINDING ACTIVITY OF ANTIGEN WHICH VARIABLE DEPENDING ON THE CONCENTRATION OF COMPOUNDS AND THE LIBRARY OF THE SPECIFIED MOLECULES
AR100353A1 (en) 2014-05-08 2016-09-28 Chugai Pharmaceutical Co Ltd ADDRESS DRUG TO GLIPICANO 3 (GPC3) THAT IS MANAGED TO A PATIENT RESPONDING TO THERAPY WITH ADDRESS DRUGS TO GPC3
US9926377B2 (en) * 2014-05-22 2018-03-27 Genentech, Inc. Anti-GPC3 antibodies and immunoconjugates
MA40764A (en) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENT INDUCING CYTOTOXICITY
CN104829704B (en) * 2014-12-15 2016-08-17 河北省科学院生物研究所 A kind of glypican GPC3 protein fragments and application thereof and the hybridoma cell strain of preparation
KR101838645B1 (en) 2014-12-19 2018-03-14 추가이 세이야쿠 가부시키가이샤 Anti-c5 antibodies and methods of use
WO2016098357A1 (en) 2014-12-19 2016-06-23 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
EP3245219B1 (en) * 2015-01-16 2020-04-08 GlyP Holdings Pty Limited Glypican epitopes and uses thereof
JP2018510842A (en) 2015-02-05 2018-04-19 中外製薬株式会社 Antibodies comprising ion concentration dependent antigen binding domains, Fc region variants, antibodies that bind to IL-8, and uses thereof
RU2730590C2 (en) 2015-02-27 2020-08-24 Чугаи Сейяку Кабусики Кайся Composition for treating diseases associated with il-6
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
WO2017002934A1 (en) 2015-07-01 2017-01-05 中外製薬株式会社 Gpc3-targeted therapeutic agent administered to patient in whom gpc3-targetd therapeutic ag
WO2017020812A1 (en) * 2015-08-03 2017-02-09 科济生物医药（上海）有限公司 Antibody against glypican-3 and application thereof
KR101796688B1 (en) 2015-10-29 2017-12-01 재단법인 목암생명과학연구소 Novel Antibody Against Glypican 3, and Pharmaceuitical Composition Comprising the Same
EP4382127A3 (en) * 2015-11-09 2024-08-28 The Children's Hospital of Philadelphia Glypican 2 as a cancer marker and therapeutic target
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
CA3004288A1 (en) 2015-12-28 2017-07-06 Nobuyuki Tanaka Method for promoting efficiency of purification of fc region-containing polypeptide
TW202214700A (en) 2016-03-14 2022-04-16 日商中外製藥股份有限公司 Cell injury inducing therapeutic drug for use in cancer therapy
KR102046235B1 (en) 2016-03-15 2019-11-18 추가이 세이야쿠 가부시키가이샤 Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies
TWI693940B (en) 2016-08-05 2020-05-21 日商中外製藥股份有限公司 Composition for the treatment or prevention of IL-8 related diseases
EP3502250B1 (en) 2016-08-22 2024-04-24 Chugai Seiyaku Kabushiki Kaisha Gene-modified rodent expressing human gpc3 polypeptide
AU2017364818A1 (en) 2016-11-28 2019-05-23 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand binding activity
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to il-6 and neutrophils
US20200216542A1 (en) 2017-09-20 2020-07-09 Chugai Seiyaku Kabushiki Kaisha Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent
TW202402792A (en) 2017-11-28 2024-01-16 日商中外製藥股份有限公司 Ligand-binding molecule having adjustable ligand-binding activity
AR114112A1 (en) 2018-02-15 2020-07-22 Seattle Genetics Inc GLIPICAN 3 ANTIBODIES AND CONJUGATES THEREOF
US20210253672A1 (en) 2018-05-30 2021-08-19 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule containing single domain antibody
CN112368298A (en) 2018-06-22 2021-02-12 凯德药业股份有限公司 Chimeric transmembrane proteins and uses thereof
EP3860716A2 (en) 2018-10-01 2021-08-11 Adicet Bio Inc. Compositions and methods regarding engineered and non-engineered gamma-delta -t cells for treatment of solid tumors
BR112021007175A2 (en) 2018-10-23 2021-08-10 Dragonfly Therapeutics, Inc. proteins fused to heterodimeric FC
US20220153875A1 (en) 2019-03-19 2022-05-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing antigen-binding domain of which binding activity to antigen is changed depending on mta, and library for obtaining said antigen-binding domain
WO2020246567A1 (en) 2019-06-05 2020-12-10 中外製薬株式会社 Protease substrate, and polypeptide including protease cleavage sequence
AU2020288499A1 (en) 2019-06-05 2022-01-27 Chugai Seiyaku Kabushiki Kaisha Antibody cleavage site-binding molecule
AU2020296878B2 (en) 2019-06-21 2023-04-20 Kite Pharma, Inc. TGF-beta receptors and methods of use
JP2023522972A (en) 2020-04-22 2023-06-01 ドラゴンフライ セラピューティクス， インコーポレイテッド Formulations, Dosing Regimens, and Manufacturing Processes for Heterodimeric Fc Fusion Proteins
CN116194124A (en) 2020-07-31 2023-05-30 中外制药株式会社 Pharmaceutical composition comprising cells expressing chimeric receptors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
JPH04228089A (en) 1990-05-15 1992-08-18 Kanegafuchi Chem Ind Co Ltd Agent for treatment and prevention of hypercalcemia
WO1995014041A1 (en) * 1993-11-19 1995-05-26 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human medulloblastomatous cell
JP3587664B2 (en) 1996-10-04 2004-11-10 中外製薬株式会社 Reshaped human anti-HM1.24 antibody
UA76934C2 (en) * 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
JP4228089B2 (en) 1997-03-11 2009-02-25 株式会社ニコン Overcurrent detection mechanism and electronic flash device using the same
US7361336B1 (en) * 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
IL135221A0 (en) * 1997-10-03 2001-05-20 Chugai Pharmaceutical Co Ltd Natural humanized antibody and methods for the preparation thereof
JP3445153B2 (en) * 1998-06-04 2003-09-08 富士通株式会社 Device and method for temporary use of telephone numbers
WO2001013940A1 (en) * 1999-08-23 2001-03-01 Chugai Seiyaku Kabushiki Kaisha Hm1.24 antigen expression potentiators
CN101240022B (en) * 2001-06-22 2012-07-18 中外制药株式会社 Cell proliferation inhibitors containing anti-glypican 3 antibody

Also Published As

Publication number Publication date
ATE483801T1 (en) 2010-10-15
JP2009024020A (en) 2009-02-05
PT1411118E (en) 2008-12-09
US20110002922A1 (en) 2011-01-06
KR20090107091A (en) 2009-10-12
AU2002315857B2 (en) 2007-07-26
JP2005225892A (en) 2005-08-25
CY1113854T1 (en) 2016-07-27
PT2208784E (en) 2013-04-03
US8263077B2 (en) 2012-09-11
CN1314803C (en) 2007-05-09
HK1120522A1 (en) 2009-04-03
JP2008120828A (en) 2008-05-29
CN1688692A (en) 2005-10-26
EP1411118A1 (en) 2004-04-21
US20040236080A1 (en) 2004-11-25
KR100877176B1 (en) 2009-01-07
JP2007051159A (en) 2007-03-01
JP4281869B2 (en) 2009-06-17
DK1411118T3 (en) 2008-11-17
KR100953520B1 (en) 2010-04-21
US7744880B2 (en) 2010-06-29
ES2312586T3 (en) 2009-03-01
EP1411118B1 (en) 2008-09-03
AU2007201255B2 (en) 2010-03-11
ATE407204T1 (en) 2008-09-15
CN101240022B (en) 2012-07-18
JP2007238632A (en) 2007-09-20
EP1780273A1 (en) 2007-05-02
EP1411118A4 (en) 2005-01-26
AU2007201255A1 (en) 2007-04-19
JPWO2003000883A1 (en) 2004-10-07
CN101240022A (en) 2008-08-13
CA2451493C (en) 2016-08-23
DE60228721D1 (en) 2008-10-16
DK2208784T3 (en) 2013-03-18
KR20040030699A (en) 2004-04-09
ES2353335T3 (en) 2011-03-01
US20070172488A1 (en) 2007-07-26
WO2003000883A1 (en) 2003-01-03
KR20080077295A (en) 2008-08-21
JP2009161565A (en) 2009-07-23
EP2208784B1 (en) 2013-01-02
ES2399028T3 (en) 2013-03-25
EP2208784A1 (en) 2010-07-21
HK1079547A1 (en) 2006-04-07
CA2451493A1 (en) 2003-01-03
JP4347402B2 (en) 2009-10-21
EP1780273B1 (en) 2010-10-06
JP5596935B2 (en) 2014-09-24

Similar Documents

Publication Publication Date Title
DE60237929D1 (en) Cell proliferation inhibitors containing anti-glypican 3 antibodies
ECSP105739A (en) NEUTRALIZATION ANTIBODIES AGAINST GDF-8
BRPI0113286B8 (en) substituted pyrazoles and pharmaceutical composition comprising the same.
AR091405A2 (en) OMEGA-CARBOXIARIL DIFENIL UREA REPLACED WITH FLUORO AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
BR0107942A (en) Slow Release Protein Polymers
CO4830493A1 (en) ANTIBODIES AGAINST HUMAN CD40
CY1106766T1 (en) PYRIDINE DERIVATIVES AS RAF KINASE INHIBITORS
TR199802505T2 (en) Use of an inhibitor of the cellular NA+/H+ exchanger (NHE) in the manufacture of a drug.
DE69934698D1 (en) MEDIUM FOR PREVENTING OR TREATING PANCREATITIS CONTAINING ANTI-IL-6 RECEPTOR ANTIBODIES AS ACTIVE COMPONENTS
SE0102327D0 (en) A novel engineered superantigen for human therapy
GB0209891D0 (en) Novel compounds
CL2003002767A1 (en) ORAL COMPOSITION THAT INCLUDES A FILM CONTAINING A FUNCTIONAL MATERIAL, IN A VEHICLE, USEFUL FOR ORAL CARE.
BR0313197A (en) Cytotoxic agents containing potent taxanes and their therapeutic use
BR0309278A (en) Compound, composition, methods for modulating ksp kinesin activity, for inhibiting ksp, for the treatment of a cell proliferative disease, and use of a compound
EA200500300A1 (en) CYTOTOXIC AGENTS CONTAINING NEW STRONGLY ACTIVE TAXANS, AND THEIR THERAPEUTIC APPLICATION
NO973017D0 (en) New trienoic retinoid compounds and methods
BR0315604A (en) Controlled release composition for oral drug administration
BR0315247A (en) Composition, pharmaceutical composition, method of treatment for a cell proliferative disease, and kit
TR200002203T2 (en) Treatment of follicular lymphomas using inhibitors of the lysophoxin (LT) expression pathway.
NO20010140D0 (en) Chemotaxin-inhibiting protein of Staphylo-Coccus (CHIPS) and its use
DK1368022T3 (en) Use of a bottle containing an oxaliplatin solution
DK1438411T3 (en) Use of aminogylcoside resistance gene
ATE506960T1 (en) DRUG AND USE FOR TUMOR THERAPY
NO20033189D0 (en) Control Means
DE69825307D1 (en) USE OF PROTEIN H AS A CYTOSTATIC ACTIVE SUBSTANCE